14 Result(s)

Article

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP),...

Mingchao **e, Miljenka Vuko, Jaime Rodriguez-Canales… in Molecular Cancer (2024)

Article

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, cau...

Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato… in Targeted Oncology (2024)

Article

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report

The management of malignancy post kidney transplantation includes reduction in immunosuppression and referral to an oncologist management of their malignancy. Recent advances in oncology have resulted in the a...

Jonathan W. Goldman, Basmah Abdalla, Melody A. Mendenhall, Anthony Sisk… in BMC Nephrology (2018)

Article

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

Background The signaling protein p38 mitogen-activated protein kinase (MAPK) regulates the tumor cell microenvironment, modulating cell survival, migration, and invasion. This phase 1 study evalu...

Jonathan W. Goldman, Lee S. Rosen, Anthony W. Tolcher… in Investigational New Drugs (2018)

Article

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune...

Manjima Dhar, Jessica Wong, James Che, Melissa Matsumoto… in Scientific Reports (2018)

Article

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow t...

Saroj Vadhan-Raj, Rafat Abonour, Jonathan W. Goldman… in Journal of Hematology & Oncology (2017)

Article

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Andreas Lundqvist, Vincent van Hoef, **aonan Zhang… in Journal for ImmunoTherapy of Cancer (2016)

Article

Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Nature Communications 7: Article number: 11815 (2016); Published 10 June 2016; Updated 14 November 2016 Previous work by Del Re et al. describing the emergence of KRAS mutations following treatment of non-smal...

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy… in Nature Communications (2016)

Article

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients trea...

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy… in Nature Communications (2016)

Article

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.

Gerald S. Falchook, **aofei Zhou, Karthik Venkatakrishnan, Razelle Kurzrock… in Drugs in R&D (2016)

Article

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Johanna C. Bendell, Lee S. Rosen, Robert J. Mayer… in Cancer Chemotherapy and Pharmacology (2016)

Article

Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation

Mi-Heon Lee, Jane Yanagawa, Rui Li, Tonya C Walser… in Journal for ImmunoTherapy of Cancer (2015)

Article

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

To evaluate safety of TAS-102 administered twice daily (bid) on days 1–5 and 8–12 of a 4-week cycle, confirm feasibility of the Japanese recommended dose (RD), 35 mg/m², in Western patients with metastatic colore...

Johanna C. Bendell, Lee S. Rosen, Robert J. Mayer… in Cancer Chemotherapy and Pharmacology (2015)

Article

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.

Jonathan W Goldman, Robert N Raju, Gregory A Gordon, Iman El-Hariry… in BMC Cancer (2013)